• CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024

    المصدر: Nasdaq GlobeNewswire / 06 مايو 2024 08:30:00   America/New_York

    BERKELEY HEIGHTS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2024, before the market opens on Thursday, May 9, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

    Thursday, May 9th @ 8:30am ET
    Domestic:1-888-886-7786
    International:1-416-764-8658
    Conference ID:32817785
    Webcast:Webcast Link
      

    About CorMedix

    CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023 and launched in inpatient settings in April 2024. CorMedix anticipates the commercial launch of DefenCath in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

    Investor Contact:

    Dan Ferry
    Managing Director
    LifeSci Advisors
    daniel@lifesciadvisors.com
    (617) 430-7576


    Primary Logo

شارك على،